Drug Profile
DLMG
Latest Information Update: 04 Jul 2000
Price :
$50
*
At a glance
- Originator Scotia Holdings [CEASED]
- Class Antihyperglycaemics
- Mechanism of Action Prostaglandin synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 04 Jul 2000 Discontinued-Preclinical for Diabetic complications in United Kingdom (Unknown route)
- 18 Feb 2000 No-Development-Reported for Diabetic complications in United Kingdom (Unknown route)
- 22 Nov 1996 Preclinical development for Diabetic complications in United Kingdom (Unknown route)